Bank of America Securities analyst Jason Gerberry has reiterated their neutral stance on UTHR stock, giving a Hold rating on August 27.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jason Gerberry has given his Hold rating due to a combination of factors related to United Therapeutics’ recent developments and market positioning. The company reported unexpectedly positive results from its TETON-2 trial for idiopathic pulmonary fibrosis (IPF), which led to a significant stock price increase. Despite this, the rating remains Neutral due to limited catalysts following the trial and potential competitive challenges.
While the TETON-2 results de-risk the program and suggest a strong market entry for Tyvaso in the IPF space, the competitive landscape poses challenges. Tyvaso is expected to enter the market about a year after a competitor’s drug, and although it may have a preferable toxicity profile, it faces dosing disadvantages. The company’s plans to expedite regulatory review and the potential for orphan drug exclusivity are positive, but these factors are balanced by the competitive environment and the need for further data from the TETON-1 trial.
According to TipRanks, Gerberry is a 4-star analyst with an average return of 4.5% and a 53.80% success rate. Gerberry covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, United Therapeutics, and Teva Pharmaceutical.